Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419360 | PMC |
| http://dx.doi.org/10.1007/s10072-020-04335-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine.
JAMA Neurol
January 2025
Geriatric Research Education and Clinical Center, North Florida/South Georgia Veterans Health System, Gainesville, Florida.
Importance: Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP mAbs) offer effective migraine-specific preventive treatment. However, concerns exist about their potential cardiovascular risks due to CGRP blockade.
Objective: To compare the incidence of cardiovascular disease (CVD) between Medicare beneficiaries with migraine who initiated anti-CGRP-mAbs vs onabotulinumtoxinA in the US.
Health equity, care access and quality in headache - part 2.
J Headache Pain
December 2023
Headache Group, Wolfson SPaRC, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Background: Headache disorders are a global public health concern affecting diverse populations. This review examines headache service organizations in low-, middle-, and high-income countries. It addresses global challenges in pharmacological headache treatment, with a focus on safety, tolerability, reproductive and child health, and outlines disparities in accessing innovative treatments worldwide.
View Article and Find Full Text PDFEfficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review.
Headache
November 2022
Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Article Synopsis
- Galcanezumab, a monoclonal antibody targeting CGRP, shows positive outcomes in treating episodic cluster headache (ECH), but its effectiveness in chronic cluster headache (CCH) had not previously been confirmed.
- A case series of patients treated with galcanezumab at a headache clinic revealed significant improvements, with over 50% frequency reduction in CCH patients and a rapid end to ECH bouts.
- The findings suggest galcanezumab could be beneficial for refractory cluster headache patients and support further clinical trials to explore its use in this area.
Preventive treatment of refractory chronic cluster headache: systematic review and meta-analysis.
J Neurol
February 2023
Neurology Department, "La Paz" University Hospital, P.º de la Castellana 261, 28046, Madrid, Spain.
Background: Preventive treatment for refractory chronic cluster headache (rCCH) is challenging and many therapies have been tried.
Objective: To study what could be considered the therapy of choice in rCCH through a systematic review and meta-analysis.
Methods: This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache.
Curr Pain Headache Rep
September 2022
Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, No. 201, Sec. 2, Shi-Pai Rd, Taipei, Taiwan, 11217.
Purpose Of Review: Chronic cluster headache (CH) substantially affects patients' quality of life, and treatment remains challenging. The current article reviewed controlled studies for new treatment options targeting calcitonin gene-related peptide (CGRP) or its receptors in CH and discussed the current gaps and future directions for the treatment of chronic CH.
Recent Findings: Two anti-CGRP monoclonal antibodies (i.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!